Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina develops DNA sequencing, array-based, informatics and proteomics technologies for research, clinical and applied markets. Company news commonly covers sequencing instruments and consumables, NovaSeq X demand, DRAGEN software releases, TruPath Genome analytical support, and applications in oncology, reproductive health, agriculture, rare disease and drug discovery.
Illumina updates also include collaborations around precision oncology testing, preventive and population genomics, pediatric cancer and rare disease data, and the Alliance for Genomic Discovery. Financial and corporate news covers revenue trends, operating margins, earnings guidance, share repurchase authorizations, acquisitions in multiomics and proteomics, and board or management changes.
Illumina (NASDAQ: ILMN) announced that CMS will reimburse its FDA-approved TruSight™ Oncology Comprehensive (TSO Comprehensive) test at $2,989.55 per test under PLA code 0543U, effective January 1, 2026. The decision places TSO Comprehensive on the Clinical Laboratory Fee Schedule and establishes a predictable reimbursement pathway for Medicare beneficiaries. Illumina says broader reimbursement will enable more labs to provide in-house comprehensive genomic profiling (CGP) and expand access to precision oncology across hospitals, networks, and regional labs. Illumina also noted clinical markets drove growth, with ~60% of sequencing consumables revenue from clinical customers in 2025.
Illumina (NASDAQ: ILMN) introduced the Illumina Billion Cell Atlas on January 13, 2026, a genome‑wide genetic perturbation dataset built to accelerate AI‑driven drug discovery.
The first tranche targets 1 billion individual cells across 200+ disease‑relevant cell lines, using CRISPR to perturb ~20,000 genes. Illumina plans a 5 billion cell resource over three years and expects to generate ~20 petabytes of single‑cell transcriptomic data within a year, processed via DRAGEN and hosted on Illumina Connected Analytics. AstraZeneca, Merck, and Eli Lilly are founding participants under an alliance framework.
Illumina (Nasdaq: ILMN) reported preliminary unaudited results for Q4 and fiscal 2025 ahead of its Jan 13, 2026 J.P. Morgan presentation. Q4 revenue ~$1.155B (up 5% vs Q4 2024; 4% constant currency) and ex-China Q4 ~$1.100B (up 7%). Fiscal 2025 revenue was approximately $4.34B (flat year-over-year) with ex-China $4.10B (up 2%). Preliminary GAAP diluted EPS: $2.14–$2.17 (Q4) and $5.42–$5.45 (FY); preliminary non-GAAP diluted EPS: $1.27–$1.30 (Q4) and $4.76–$4.79 (FY). Results are unaudited and subject to final audit; full results due Feb 5, 2026.
Illumina (NASDAQ:ILMN) will release fourth quarter and full year 2025 financial results after market close on Thursday, February 5, 2026.
Management will host a conference call at 1:30 PM PT / 4:30 PM ET on the same day. Investors can access a live webcast via the company's Investor Info website or the provided link. A replay will be posted on the website and remain available for at least 30 days.
Illumina (NASDAQ: ILMN) appointed Eric D. Green, M.D., Ph.D. as Chief Medical Officer, effective February 2, 2026. Dr. Green will report to the CEO, join the Executive Leadership Team, and lead efforts to expand clinical genomics, increase diversity of genomics data, and advance the company's medical strategy globally. The company also announced the departure of chief commercial officer Everett Cunningham, with CEO Jacob Thaysen acting as interim chief commercial officer.
Illumina (NASDAQ: ILMN) on January 6, 2026 announced Illumina Connected Multiomics, a cloud-based research software platform for integrated multiomic and multimodal analysis.
The platform, officially launched last month after input from 40 early access users, can aggregate thousands of multiomic samples, supports single-cell and spatial analyses, includes DRAGEN secondary analysis, and adds AI-enabled variant interpretation via PrimateAI and PromoterAI.
Illumina says the software aims to reduce time, cost, and complexity for researchers and enable reproducible interactive visualizations and scalable workflows for discovery and precision medicine.
Illumina (NASDAQ: ILMN) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The management presentation is scheduled for 7:30 a.m. PT (10:30 a.m. ET) with a Q&A at approximately 7:50 a.m. PT (10:50 a.m. ET). The live webcast will be available via the Events & Presentations section of Illumina's investor website, and a replay will be archived on the site for at least 30 days following the event.
Illumina (NASDAQ: ILMN) announced a collaboration and strategic investment in MyOme to support MyOme's Proactive Health (MPH) Trial and expand clinical genomics products. The MPH Trial aims to enroll beginning in 2026 and will test whole‑genome sequencing (WGS) plus MyOme's AI‑integrated risk models (IRMs) for earlier detection and prevention across cancers, cardiometabolic and rare diseases. Health economic modeling cited in the announcement estimates potential U.S. cost savings of more than $200 billion annually if WGS+IRM adoption is broad. The deal also notes continued financing support from partners including Natera, Sequoia Capital and The Duquesne Family Office.
Illumina (NASDAQ: ILMN) announced a collaboration and strategic investment in MyOme, announced Dec. 11, 2025, to support MyOme's Proactive Health (MPH) Trial and commercial product expansion.
The MPH trial aims to begin enrollment in 2026 and will evaluate whole‑genome sequencing (WGS) plus MyOme's AI‑integrated risk models (IRMs) for common chronic disease, cancer and rare disease. Health economic modeling cited in the announcement suggests potential U.S. savings of more than $200 billion per year from broad WGS+IRM adoption; the release notes U.S. annual healthcare spend of about $5 trillion. The financing also lists continued support from Natera, Sequoia Capital and The Duquesne Family Office.
Illumina (NASDAQ: ILMN) and collaborators published a Nature study on Nov 12, 2025 showing whole-genome sequencing (WGS) with DRAGEN capture nearly 90% of genetic signal across 34 common diseases and traits, addressing the "missing heritability" gap. The analysis used 347,630 WGS samples from UK Biobank and replication in the Alliance for Genomic Discovery.
Key findings: WGS outperformed whole-exome sequencing and arrays, with WES explaining 17.5% of genetic variance, arrays missing 20–40% of some rare alleles, and WGS recovering >30% of rare-variant heritability for HDL and LDL. Advanced AI tools (PrimateAI-3D, DRAGEN) improved rare-variant interpretation and drug-target discovery.